Email this article 
Hide
Show all
Case Report
Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
Submitted: 13 July 2022 | Published: 26 October 2022
About the author(s)
Linda A. Mandikiyana Chirimuta, Newlands Clinic, Ruedi Luethy Foundation, Harare, ZimbabweMargaret J. Pascoe, Newlands Clinic, Ruedi Luethy Foundation, Harare, Zimbabwe
Sara Lowe, Newlands Clinic, Ruedi Luethy Foundation, Harare, Zimbabwe
Abstract
We report two cases of dolutegravir (DTG) resistance in highly treatment experienced patients. Monitoring for treatment failure and adherence support is important in highly treatment experienced patients taking DTG.
What this study adds: Dolutegravir is the mainstay of HIV treatment programmes and emergence of drug resistance to DTG is of public health relevance.
Keywords
Metrics
Total abstract views: 2665Total article views: 3508
Crossref Citations
1. Outcomes and characteristics of patients on protease inhibitors at a tertiary level antiretroviral clinic
Michele Perks, Denasha L. Reddy, Francois Venter
Southern African Journal of HIV Medicine vol: 24 issue: 1 year: 2023
doi: 10.4102/sajhivmed.v24i1.1536
2. Research Progress on Influencing Factors of AIDS Curative Effect
金玲 刘
Advances in Clinical Medicine vol: 13 issue: 07 first page: 11153 year: 2023
doi: 10.12677/ACM.2023.1371557
3. Drug-drug interaction between dolutegravir and artemether-lumefantrine in HIV and malaria mono- and co-infections: a pharmacogenetic analysis from Ghana
Nicholas Ekow Thomford, Tracy Kellermann, Joel Adu Twum, John Anyimadu, Charné Dixon, Dennis Sappor, Dee Blackhurst, Prince Amoah Barnie, Oksana Ryabinina, Samuel Badu Nyarko, Robert Peter Biney, Martins Ekor, George B. Kyei
AIDS Research and Therapy vol: 22 issue: 1 year: 2025
doi: 10.1186/s12981-025-00787-9